Nivolumab & AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Clinical Trial Summary

The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD). The primary objective is to show efficacy of the two experimental treatment strategies. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06018129` - A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT03212404` - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers	Phase 1
Recruiting	`NCT04288726` - Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas	Phase 1
Recruiting	`NCT04486391` - Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma	Phase 3
Active, not recruiting	`NCT05008224` - Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)	Phase 2
Active, not recruiting	`NCT02684708` - Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents	Phase 3
Active, not recruiting	`NCT03226249` - PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma	Phase 2
Active, not recruiting	`NCT03739619` - Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	Phase 1/Phase 2
Completed	`NCT03327571` - B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
Recruiting	`NCT03652441` - Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma	Phase 2
Completed	`NCT02243436` - Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma	Phase 1/Phase 2
Terminated	`NCT04254107` - A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer	Phase 1
Recruiting	`NCT05714553` - NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours	Phase 1/Phase 2
Completed	`NCT02981914` - Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation	Early Phase 1
Withdrawn	`NCT04952584` - Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas	Phase 1
Withdrawn	`NCT03205891` - Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas	Phase 1
Not yet recruiting	`NCT02808520` - Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma	N/A
Recruiting	`NCT02332668` - A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)	Phase 1/Phase 2
Completed	`NCT04858568` - Immune Responses to COVID-19 Vaccination in Lymphoma Patients
Active, not recruiting	`NCT02824029` - Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	Phase 2

NCT number	NCT03004833
Study type	Interventional
Source	University of Cologne
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	February 21, 2017
Completion date	December 2023

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma — NIVAHL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms